☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Head
EMD Serono and Pfizer to Terminate P-III JAVELIN Head and Neck 100 Study Evaluating Bavencio + CRT for Squamous Cell Carcinoma of...
March 13, 2020
Debiopharm's Debio 1143 Receives the US FDA's Breakthrough Therapy Designation for Front-Line Treatment of Head and Neck Cancer
February 27, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.